Quarterly report [Sections 13 or 15(d)]

CONTINGENT PAYMENT (Details Narrative)

v3.26.3
CONTINGENT PAYMENT (Details Narrative)
9 Months Ended
Sep. 30, 2026
USD ($)
CONTINGENT PAYMENT  
Net sales and profit sharing $ 400,000
Upfront purchase price $ 400,000
Seller for purchase of assets description the Net Sales (as defined in the APA) of LUCEMYRA® and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of LUCEMYRA®. The Company shall also pay to the Seller a royalty equal to 3% of the Net Sales of LUCEMYRA® and 3% of the Net Distributable Profits
Royalty payments period 5 years